|
|
|
|
||
New buy rating...JefferiesJefferies initiates Corcept Therapeutics $CORT with Buy, PT $20, "we see Gx Korlym challenges as winnable, w/ key '214 patent PGR decision upcoming in Nov'19; relacorilant also has potential to expand market... |
return to message board, top of board |